We are about to enter into a really exciting phase for this company now with the 4 trials not far away at all. I've been of the belief that successful OSA or TBI trials would send the SP into the stratosphere but now I'm leaning towards ARDS jumping the queue and being the company maker.
IF the upcoming ARDS animal trial is successful, and I believe that will kick off soon now that we have all permits in place and product available (should get an ann very shortly around commencement), the path to commercialisation will be rapid. Hydroxychloroquine has already been approved by the FDA as a treatment for COVID-19 and I'm sure it's on that basis that Comargo has suggested that IHL-675A will be a strong candidate for FDA Emergency Use Authorisation.
The medicos would then be free to prescribe IHL-675A to patients whilst the company progresses the in-human trials; slightly disturbing the fact that it could be prescribed based on animal trials but I'm not complaining
I would not be surprised at all if the BOD had this treatment for ARDS on the roadmap long ago but possibly have brought it forward due to the prospect of it being fast tracked due to COVID-19 - there are some clever cookies on our BOD!
Onwards and upwards guys, not long to go now.
